Inogen, Inc (INGN): Price and Financial Metrics
INGN Price/Volume Stats
Current price | $8.07 | 52-week high | $14.10 |
Prev. close | $7.97 | 52-week low | $4.13 |
Day low | $7.90 | Volume | 315,800 |
Day high | $8.19 | Avg. volume | 630,508 |
50-day MA | $7.35 | Dividend yield | N/A |
200-day MA | $6.78 | Market Cap | 188.25M |
INGN Stock Price Chart Interactive Chart >
INGN POWR Grades
- INGN scores best on the Value dimension, with a Value rank ahead of 74.91% of US stocks.
- The strongest trend for INGN is in Growth, which has been heading up over the past 26 weeks.
- INGN's current lowest rank is in the Sentiment metric (where it is better than 3.57% of US stocks).
INGN Stock Summary
- With a price/sales ratio of 0.38, INOGEN INC has a higher such ratio than merely 12.24% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, INOGEN INC is reporting a growth rate of 291.01%; that's higher than 96.15% of US stocks.
- In terms of volatility of its share price, INGN is more volatile than 89.42% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to INOGEN INC are MIR, KAMN, SKLZ, VSTO, and MTX.
- INGN's SEC filings can be seen here. And to visit INOGEN INC's official web site, go to www.inogen.com.
INGN Valuation Summary
- INGN's price/sales ratio is 0.4; this is 90.48% lower than that of the median Healthcare stock.
- Over the past 120 months, INGN's price/sales ratio has gone down 3.2.
Below are key valuation metrics over time for INGN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
INGN | 2023-12-29 | 0.4 | 0.6 | -1 | -0.2 |
INGN | 2023-12-28 | 0.4 | 0.6 | -1 | -0.2 |
INGN | 2023-12-27 | 0.4 | 0.6 | -1 | -0.2 |
INGN | 2023-12-26 | 0.4 | 0.6 | -1 | -0.2 |
INGN | 2023-12-22 | 0.4 | 0.6 | -1 | -0.2 |
INGN | 2023-12-21 | 0.4 | 0.6 | -1 | -0.3 |
INGN Growth Metrics
- The 3 year price growth rate now stands at -73.57%.
- Its 2 year cash and equivalents growth rate is now at 2.42%.
- The 3 year revenue growth rate now stands at -4.82%.
The table below shows INGN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 377.241 | -37.532 | -83.772 |
2022-09-30 | 365.553 | -15.552 | -50.039 |
2022-06-30 | 353.269 | -9.063 | -28.359 |
2022-03-31 | 351.456 | 2.675 | -19.815 |
2021-12-31 | 358.003 | 23.633 | -6.333 |
2021-09-30 | 355.578 | 33.333 | 11.423 |
INGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- INGN has a Quality Grade of C, ranking ahead of 45.31% of graded US stocks.
- INGN's asset turnover comes in at 0.71 -- ranking 52nd of 186 Medical Equipment stocks.
- ATRC, BSX, and GKOS are the stocks whose asset turnover ratios are most correlated with INGN.
The table below shows INGN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.710 | 0.467 | 0.022 |
2021-03-31 | 0.661 | 0.455 | -0.057 |
2020-12-31 | 0.671 | 0.448 | -0.053 |
2020-09-30 | 0.687 | 0.440 | -0.044 |
2020-06-30 | 0.731 | 0.448 | 0.060 |
2020-03-31 | 0.821 | 0.460 | 0.140 |
INGN Price Target
For more insight on analysts targets of INGN, see our INGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $71.00 | Average Broker Recommendation | 1.92 (Hold) |
Inogen, Inc (INGN) Company Bio
Inogen develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company was founded in 2001 and is based in Goleta, California.
Latest INGN News From Around the Web
Below are the latest news stories about INOGEN INC that investors may wish to consider to help them evaluate INGN as an investment opportunity.
Inogen (INGN) Down 4.2% Since Last Earnings Report: Can It Rebound?Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEOGOLETA, Calif., November 13, 2023--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Kevin Smith as Inogen’s President and Chief Executive Officer and a member of the Board of Directors, effective immediately, succeeding Nabil Shabshab. |
Inogen (INGN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesAlthough the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
Inogen to Present at Upcoming Investor Conferences in November 2023GOLETA, Calif., November 09, 2023--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences: |
Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/YDespite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances. |
INGN Price Returns
1-mo | 28.30% |
3-mo | 46.99% |
6-mo | 54.60% |
1-year | -33.58% |
3-year | -84.05% |
5-year | -91.54% |
YTD | 46.99% |
2023 | -72.15% |
2022 | -42.03% |
2021 | -23.90% |
2020 | -34.61% |
2019 | -44.97% |
Continue Researching INGN
Want to see what other sources are saying about Inogen Inc's financials and stock price? Try the links below:Inogen Inc (INGN) Stock Price | Nasdaq
Inogen Inc (INGN) Stock Quote, History and News - Yahoo Finance
Inogen Inc (INGN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...